{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:15:33Z","timestamp":1778757333864,"version":"3.51.4"},"reference-count":47,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100021743","name":"Canadian Respiratory Research Network","doi-asserted-by":"crossref","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}],"id":[{"id":"10.13039\/501100021743","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["Unrestricted research grant"],"award-info":[{"award-number":["Unrestricted research grant"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,11,14]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Personalised management of cystic fibrosis (CF) lung disease in the era of CF transmembrane conductance regulator (CFTR) modulator therapy will require novel approaches to assess treatment response and monitor longitudinal progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated the heterogeneity of short-term response to elexacaftor-tezacaftor-ivacaftor (ETI) using\n                      <jats:sup>129<\/jats:sup>\n                      Xe MRI, multiple breath washout (MBW) and spirometry. For CFTR modulator-na\u00efve people \u22656 years old starting commercial ETI, we measured same-day\n                      <jats:sup>129<\/jats:sup>\n                      XeMRI ventilation defect per cent (VDP), lung clearance index (LCI), forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) and CF Questionnaire-Revised respiratory-domain (CFQ-R(R)) at pre-ETI baseline and up to 4\u2009months post-ETI. Baseline versus follow-up measures were compared using Wilcoxon-signed-rank tests with r effect size coefficients. Abnormal follow-up measures determined using z-scores and upper\/lower limits of normal; correlations evaluated using Spearman \u03c1 coefficients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      VDP, FEV\n                      <jats:sub>1<\/jats:sub>\n                      , LCI and CFQ-R(R) significantly improved in the total group (n=40; all p&lt;0.001, r=0.69, r=0.79, r=0.70, r=0.77) and both \u226512-year-old subgroups (n=15 FEV\n                      <jats:sub>1<\/jats:sub>\n                      &lt;80%, p=0.005\/r=0.69, p&lt;0.001\/r=0.87, p=0.004\/r=0.70, p&lt;0.001\/r=0.88; n=17 FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u226580%, p=0.003\/r=0.54, p=0.003\/r=0.74, p=0.01\/r=0.56, p=0.006\/r=0.73). VDP (p=0.008\/r=0.89), LCI (p=0.03\/r=0.83) and percent-predicted FEV\n                      <jats:sub>1<\/jats:sub>\n                      (p=0.03\/r=0.83) significantly improved in the 6\u201311-year-old subgroup, with VDP having the greatest effect size in children. VDP remained abnormal at follow-up in 21 participants with normal FEV\n                      <jats:sub>1<\/jats:sub>\n                      , whereas LCI was abnormal in 12. Baseline VDP (\u03c1=0.39\/p=0.01) and LCI (\u03c1=0.43\/p=0.008) were significantly correlated with the change in CFQ-R(R).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Though all outcome measures showed a positive response, response to ETI was heterogeneous between individuals and between\n                      <jats:sup>129<\/jats:sup>\n                      XeMRI, MBW and spirometry. Leveraging the rich information provided by multimodal tools will be critical to understanding the nature of CF lung disease and measuring response to future therapies in the era of CFTR modulators.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223687","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:13:53Z","timestamp":1765278833000},"page":"560-570","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of short-term elexacaftor-tezacaftor-ivacaftor response in cystic fibrosis using\n                    <sup>129<\/sup>\n                    Xe MRI"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-1645","authenticated-orcid":false,"given":"Rachel L","family":"Eddy","sequence":"first","affiliation":[{"name":"The University of British Columbia Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada"},{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"},{"name":"Department of Radiology, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-5130","authenticated-orcid":false,"given":"Vanessa M","family":"Diamond","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josie","family":"Chrenek","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6479-9346","authenticated-orcid":false,"given":"Girija","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sag","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Ghadymimahani","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amreen","family":"Aulakh","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney X","family":"Ha","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S","family":"Quon","sequence":"additional","affiliation":[{"name":"The University of British Columbia Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada"},{"name":"Division of Respiratory Medicine, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-8876","authenticated-orcid":false,"given":"Jonathan H","family":"Rayment","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"},{"name":"Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026051403202052000_81.6.560.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026051403202052000_81.6.560.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2026051403202052000_81.6.560.3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"2026051403202052000_81.6.560.5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older \u2013 The RECOVER Trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0219OC"},{"key":"2026051403202052000_81.6.560.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur Respir J"},{"key":"2026051403202052000_81.6.560.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.05.014"},{"key":"2026051403202052000_81.6.560.9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026051403202052000_81.6.560.10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026051403202052000_81.6.560.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0021OC"},{"key":"2026051403202052000_81.6.560.12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"2026051403202052000_81.6.560.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-895OC"},{"key":"2026051403202052000_81.6.560.14","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00408-2020","article-title":"Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases","volume":"6","author":"Stahl","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026051403202052000_81.6.560.15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026051403202052000_81.6.560.16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.17","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/jmri.27030","article-title":"Current state of the art MRI for the longitudinal assessment of cystic fibrosis","volume":"52","author":"Woods","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"2026051403202052000_81.6.560.18","doi-asserted-by":"crossref","unstructured":"Smith LJ , Horsley A , Bray J , et al . The assessment of short and long term changes in lung function in CF using (129)Xe MRI. Eur Respir J 2020;2000441. doi:10.1183\/13993003.00441-2020","DOI":"10.1183\/13993003.00441-2020"},{"key":"2026051403202052000_81.6.560.19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/jmri.29605","article-title":"Same-Day Repeatability and 28-Day Reproducibility of Xenon MRI Ventilation in Children With Cystic Fibrosis in a Multi-Site Trial","volume":"61","author":"Walkup","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"2026051403202052000_81.6.560.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.07.008"},{"key":"2026051403202052000_81.6.560.21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1164\/rccm.201705-0894LE","article-title":"Longitudinal Assessment of Children with Mild Cystic Fibrosis Using Hyperpolarized Gas Lung Magnetic Resonance Imaging and Lung Clearance Index","volume":"197","author":"Smith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jcf.2020.11.019","article-title":"Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis","volume":"20","author":"Willmering","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026051403202052000_81.6.560.23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02188-2018","article-title":"Hyperpolarised 129Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis","volume":"53","author":"Rayment","year":"2019","journal-title":"Eur Respir J"},{"key":"2026051403202052000_81.6.560.24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jcf.2024.09.021","article-title":"Assessing 129Xe multi-breath washout MRI response to elexacaftor\/tezacaftor\/ivacaftor intervention in pediatric CF","volume":"24","author":"Alam","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026051403202052000_81.6.560.25","article-title":"Hyperpolarized 129Xe pulmonary magnetic resonance imaging and multiple breath washout response to elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis","volume":"207","author":"Diamond","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.26","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(23)01043-3","article-title":"109 Hyperpolarized 129Xe pulmonary MRI and multiple-breath washout to measure response to elexacaftor-tezacaftor-ivacaftor therapy in children","volume":"22","author":"Diamond","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026051403202052000_81.6.560.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4.2347"},{"key":"2026051403202052000_81.6.560.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2026051403202052000_81.6.560.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202205-0963OC"},{"key":"2026051403202052000_81.6.560.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069712"},{"key":"2026051403202052000_81.6.560.31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00524-2024","article-title":"Global Lung Function Initiative reference values for multiple breath washout indices","volume":"64","author":"Ramsey","year":"2024","journal-title":"Eur Respir J"},{"key":"2026051403202052000_81.6.560.32","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/mrm.28985","article-title":"Protocols for multi-site trials using hyperpolarized 129 Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the 129 Xe MRI clinical trials consortium","volume":"86","author":"Niedbalski","year":"2021","journal-title":"Magn Reson Med"},{"key":"2026051403202052000_81.6.560.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2011.10.007"},{"key":"2026051403202052000_81.6.560.34","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7952","article-title":"The Age-dependent Upper Limit of Normal for Hyperpolarized 129 Xe MRI Ventilation Defect Percent in Healthy Individuals Using a Multi-center Database","volume":"211","author":"Bdaiwi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202052000_81.6.560.35","doi-asserted-by":"crossref","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences. 2nd edition ed. New York: Routledge, 2013.","DOI":"10.4324\/9780203771587"},{"key":"2026051403202052000_81.6.560.36","unstructured":"Cystic Fibrosis Canada . The Canadian cystic fibrosis registry 2020 annual report. 2020."},{"key":"2026051403202052000_81.6.560.37","doi-asserted-by":"crossref","unstructured":"Ratjen FA , Stanojevic S , Munidasa S , et al . Multi-center Study of Hyperpolarized Xenon MRI in Children with Cystic Fibrosis Following Initiation of CFTR Modulator Therapy (HyPOINT). Ann Am Thorac Soc 2025. doi:10.1513\/AnnalsATS.202501-028OC","DOI":"10.1513\/AnnalsATS.202501-028OC"},{"key":"2026051403202052000_81.6.560.38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00434-9"},{"key":"2026051403202052000_81.6.560.39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026051403202052000_81.6.560.40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026051403202052000_81.6.560.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202402-0389CI"},{"key":"2026051403202052000_81.6.560.42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026051403202052000_81.6.560.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.02.003"},{"key":"2026051403202052000_81.6.560.44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026051403202052000_81.6.560.45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jmri.29041","article-title":"Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor\/Tezacaftor\/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times","volume":"60","author":"David","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"2026051403202052000_81.6.560.46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00330-023-09912-6","article-title":"Effect of CFTR modulator therapy with elexacaftor\/tezacaftor\/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients","volume":"34","author":"Klime\u0161","year":"2024","journal-title":"Eur Radiol"},{"key":"2026051403202052000_81.6.560.47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:22:21Z","timestamp":1778754141000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/thorax-2025-223687"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223687","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}